MedTrace Logo

Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer

NCT02824575 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2022-04-04

No results posted yet for this study

Summary

The purpose of this study is to determine the safety and tolerability of rebastinib when combined with antitubulin therapy with paclitaxel or eribulin in patients with advanced breast cancer.

Conditions

  • Breast Cancer
  • Breast Adenocarcinoma
  • Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
  • Recurrent Breast Carcinoma
  • Stage IV Breast Cancer

Interventions

DRUG

Rebastinib

50 mg or 100 mg po BID continuously. Cycle duration: 21 days. Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.

DRUG

Paclitaxel

Paclitaxel 80 mg/m2 weekly. Cycle duration = 21 days. Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.

DRUG

Eribulin Mesylate

Eribulin 1.4 mg/m2 day 1 \& 8. Cycle duration : 21 days. Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.

Sponsors & Collaborators

  • Deciphera Pharmaceuticals, LLC

    collaborator INDUSTRY

  • Albert Einstein College of Medicine

    collaborator OTHER

  • Montefiore Medical Center

    lead OTHER

Principal Investigators

  • Jesus D Anampa Mesias, M.D · Montefiore Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-07-31
Primary Completion
2021-12-27
Completion
2021-12-27

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02824575 on ClinicalTrials.gov